Home » Topics » Regulatory

Regulatory
RSS

Canadian approval for Gleevec for newly diagnosed Ph+ CML

Oct. 30, 2003

Raptiva approved for chronic, moderate to severe plaque psoriasis

Oct. 30, 2003

Levaquin approved for five-day treatment of CAP

Oct. 30, 2003

Cyberonics submits PMA-S for VNS Therapy

Oct. 29, 2003

Remicade approved in E.U. for maintenance dosing in fistulizing Crohn's disease

Oct. 27, 2003

Starlix approved in combination with TZD for type 2 diabetes

Oct. 27, 2003

Approvable letter issued for Foradil Certihaler

Oct. 24, 2003

Approvable letter issued for expansion of Provigil labeling

Oct. 23, 2003

Once-weekly Enbrel approved

Oct. 23, 2003

Lexiva, the only protease inhibitor offering flexible dosing, approved in U.S.

Oct. 22, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...